A narrative meta-synthesis of how people with schizophrenia experience facilitators and barriers in using antipsychotic medication: Implications for healthcare professionals

Salzmann‐Erikson, Martin; Sjödin, Marie

doi:10.1016/j.ijnurstu.2018.05.003

Cited by 27 publications

(28 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to these findings a recent questionnaire study showed that both physicians and patients felt that patients were highly involved in the decision to switch to PP3M [22]. This is in line with previous research highlighting the importance of perceiving the source of information as reliable [29] and of having good relationships with health care professionals [18]. Most participants in our study had close relationships to both private and professional contacts (Table 1).…”

Section: Results Discussionsupporting

confidence: 90%

See 1 more Smart Citation

Patients’ perspectives on three-monthly administration of antipsychotic treatment with paliperidone palmitate – a qualitative interview study

Rise

Stølan

Erdner

et al. 2020

Nordic Journal of Psychiatry

View full text Add to dashboard Cite

Introduction: Three-monthly dosage of paliperidone palmitate entails longer time to relapse after discontinuation, is similarly tolerable and safe compared to monthly injections of paliperidone palmitate and is beneficial for the caregivers. However, few studies have so far explored in depth the patients' experiences with paliperidone palmitate medication every three months, or with switching from monthly to three-monthly injections of paliperidone palmitate. Material and methods: A qualitative study based on individual interviews with persons with schizophrenia who receive three-monthly paliperidone palmitate in Norway, Sweden and Denmark. Data was analysed according to qualitative content analysis. Results: Twenty-four patients, 16 men and 8 women, took part in individual interviews. The patients' mental health care professionals mainly recommended the switch to three-monthly paliperidone palmitate, and few or no disadvantages were described. According to the patients, three-monthly paliperidone palmitate had several advantages, such as less frequent injections, less administration and planning and less focus on the illness. In addition, the participants described feeling more stability, being more physically and socially active, and that improvement processes were supported. For some, the use involved practical and economic challenges, and some worried whether the medicine 'wore off' before the next injection. According to the patients, switching to three-monthly paliperidone palmitate did not influence the frequency or content of patients' interaction with health care professionals. Conclusion: Switching from monthly to three-monthly injections with paliperidone palmitate seems to be experienced as advantageous for patients with schizophrenia.

show abstract

Section: Results Discussionsupporting

confidence: 90%

“…Overall, research on the patients' perspectives on and experiences with antipsychotic medication is scarce [18]. Studies have shown that health care professionals prescribing PP3M are mostly satisfied with the efficacy and tolerability of the medications [19,20].…”

Section: Introductionmentioning

confidence: 99%

Patients’ perspectives on three-monthly administration of antipsychotic treatment with paliperidone palmitate – a qualitative interview study

Rise

Stølan

Erdner

et al. 2020

Nordic Journal of Psychiatry

View full text Add to dashboard Cite

show abstract

“…The majority of patients included in our study had a documented diagnosis of schizophrenia. Treatment nonadherence rates in this population range from 26.5% to 68.8%, 17 which is significant because this increases the risk of suicide, psychotic relapse, and hospital admission. 18 Recent evidence suggests that LAI antipsychotics reduce the risk of rehospitalization in patients with schizophrenia compared to oral antipsychotics 19,20 ; therefore, these agents are often used at BUMCS in patients with a history of treatment nonadherence.…”

Section: Discussionmentioning

confidence: 98%

Start low, go fast? Antipsychotic titration patterns at an inpatient psychiatric hospital

Vadiei

Chien

Enwereji

et al. 2020

Mental Health Clinician

View full text Add to dashboard Cite

Introduction Antipsychotics are commonly used to treat psychotic symptoms and severe mental illnesses. Treatment guidelines recommend antipsychotics be titrated quickly to therapeutic effect in the acute setting but acknowledge that determining the optimal dose is complicated by a delay between treatment initiation and therapeutic response. The purpose of this study was to evaluate antipsychotic titration patterns in an inpatient psychiatric hospital. Methods This study is a retrospective chart review of adult patients admitted to a teaching hospital and initiated on an antipsychotic for treatment of psychosis between January and December 2018. Patients were excluded if they had substance-induced psychosis, delirium, were prescribed >1 antipsychotic, or had no antipsychotic dose changes. The primary outcome was the average titration rate of the newly initiated antipsychotic. Secondary outcomes included differences in titration rate between involuntary and voluntary admissions and other antipsychotic characteristics. Results Of 149 patients included, the majority had a primary diagnosis of schizophrenia. Antipsychotics were titrated on average every 2 days regardless of admission type. Eighteen percent of patients were titrated to guideline-recommended maximum doses, and it took, on average, 3 days for patients to reach their final dose during hospitalization. Average length of stay was 9 days, and 43.6% of patients were readmitted within 1 year. Discussion Antipsychotics are titrated rapidly in the inpatient setting despite a lack of evidence regarding the impact of titration rate on clinical outcomes. Further studies comparing slow versus rapid titration strategies are needed to elucidate the impact of this on patient outcomes.

show abstract

“…Knowledge of service user perspectives on the antipsychotic treatment of schizophrenia is limited . A number of studies have compared oral treatment with long‐acting injections (LAIs) .…”

Section: Purposementioning

confidence: 99%

“I live, I don't work, but I live a very normal life”—A qualitative interview study of Scandinavian user experiences of schizophrenia, antipsychotic medication, and personal recovery processes

Møllerhøj

Stølan

Erdner

et al. 2020

Perspect Psychiatr Care

View full text Add to dashboard Cite

Purpose: To illuminate user experiences of schizophrenia, reasons for receiving antipsychotic medication, and encounters with mental health services.Design and Methods: 24 semistructured qualitative research interviews with schizophrenia patients treated with 3-monthly paliperidone palmitate across Scandinavia were synthesized in qualitative content analysis.Findings: Participants describe considerable challenges in everyday functioning.Simultaneously, they rate their current mental and physical well-being high and seem satisfied with their lives. These pathways indicate personal recovery.Practice Implications: The participants emphasize the importance of trustful relations with healthcare professionals, therapeutic conversations, antipsychotic medication in a 3-monthly formulation, and support from relatives. K E Y W O R D S illness insight, personal recovery, PP3M, schizophrenia, service user perspectives 1 | PURPOSE Knowledge of service user perspectives on the antipsychotic treatment of schizophrenia is limited. 1 A number of studies have compared oral treatment with long-acting injections (LAIs). 2-6 This

show abstract

A narrative meta-synthesis of how people with schizophrenia experience facilitators and barriers in using antipsychotic medication: Implications for healthcare professionals

Cited by 27 publications

References 57 publications

Patients’ perspectives on three-monthly administration of antipsychotic treatment with paliperidone palmitate – a qualitative interview study

Patients’ perspectives on three-monthly administration of antipsychotic treatment with paliperidone palmitate – a qualitative interview study

Start low, go fast? Antipsychotic titration patterns at an inpatient psychiatric hospital

“I live, I don't work, but I live a very normal life”—A qualitative interview study of Scandinavian user experiences of schizophrenia, antipsychotic medication, and personal recovery processes

Contact Info

Product

Resources

About